SCHEMBL1480315

SCHEMBL1480315

Clc1ccc(-c2c[nH]c(C=Cc3cccc4ccccc34)n2)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.41
LMNA P02545 3/20 0.41
NPC1 O15118 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
ALPL P05186 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
ALPG P10696 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GUSB P08236 1/20 0.38
CRHR1 P34998 2/20 0.37
ELANE P08246 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480314 1.00 RAB9A (0.41) RAB9ALMNANPC1KDM4EMEN1
SCHEMBL1480665 0.82 HPGD (0.48) RAB9ALMNANPC1KDM4EMEN1
SCHEMBL1480661 0.82 HPGD (0.48) RAB9ALMNANPC1KDM4EMEN1
SCHEMBL1481354 0.82 TUBB4A (0.46) RAB9ALMNANPC1KDM4EMEN1
SCHEMBL1481357 0.82 TUBB4A (0.46) RAB9ALMNANPC1KDM4EMEN1
SCHEMBL6462917 0.81 SMN1; SMN2 (0.46) RAB9ALMNANPC1KDM4EMEN1
SCHEMBL1480848 0.81 RELA (0.41) RAB9ALMNANPC1KDM4EMEN1
SCHEMBL1480844 0.81 RELA (0.41) RAB9ALMNANPC1KDM4EMEN1
SCHEMBL1480794 0.79 MAPT (0.40) RAB9ALMNANPC1KDM4EMEN1
SCHEMBL1480791 0.79 MAPT (0.40) RAB9ALMNANPC1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ RAB9A 3266/4885LMNA 4711/4885NPC1 3792/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ RAB9A 3266/4885LMNA 4711/4885NPC1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.